Panitumumab data presented at ESMO 2016: depth of response and selecting the right patients
How do we select the urothelial carcinoma patients who will benefit from checkpoint inhibitors?
Neoadjuvant therapy with trametinib and dabrafenib in high risk resectable BRAF-mutant melanoma
Rodabe N. Amaria
Drugs with low response rates - should they always be offered to patients?
ECCO 2017: important trials in bladder cancer and renal cell carcinoma